Global Atrial Fibrillation Drugs Market is expected to grow at a CAGR of 3.2% during the forecast period 2020-2027

A new research report published by Fior Markets with the title Atrial Fibrillation Drugs Market Size By Atrial Fibrillation Type (Persistent, Paroxysmal, Permanent), Products (Antiarrhythmic Drugs, Anticoagulant Drugs {Novel Oral Anticoagulants, Vitamin K Antagonists}), Application, Route of Administration, End-use, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2020 to 2027

The global atrial fibrillation drugs market is expected to grow from USD 13.51 billion in 2019 to USD 17.39 billion by 2027, at a CAGR of 3.2% during the forecast period 2020-2027. North America is expected to dominate the market during the forecast period due to high geriatric population and increasing prevalence of cardiovascular diseases. USA is the largest market in the region with a high concentration of leading players of the market. Asia-Pacific region is anticipated to witness the highest growth rate during the forecast period. The growth rate can be attributed to increasing investments in the healthcare infrastructure, leading to large-scale developments of hospitals and private clinics. The widespread adoption of western culture and sedentary lifestyles is causing a rise in the number of cardiovascular diseases and other health-related issues in the population. This is a significant factor contributing to market growth.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/418211/request-sample

The leading players of the market include CardioFocus Inc., AtriCure Inc., Endoscopic Technologies Inc., Boston Scientific Corporation, Johnson & Johnson Ltd., Sanofi-Aventis, Bristol-Myers Squibb Corporation, Biosense Webster Inc., Boehringer Ingelheim GmbH, and St. Jude Medical Inc. A few companies hold a significant market share with renowned brand position and a robust financial position. The companies are focusing on mergers and acquisitions, market expansion, and innovative product launches. In March 2020, the U.S. FDA approved Sotalol IV indications in the patients resulting in increased patient satisfaction, reduced stay at hospitals and less costs.

This study delivers a comprehensive analysis of types of atrial fibrillation, product, application, route of administration, end-use, and regions. On the basis of atrial fibrillation type, the market can be divided into persistent, paroxysmal, and permanent. The paroxysmal condition is expected to dominate the market with a large number of people suffering from it. The disease does not threaten life; however, it causes serious consequences. On the basis of the product, the market can be divided into antiarrhythmic drugs and anticoagulant drugs. The anticoagulant drugs can be further subdivided into novel oral anticoagulants and vitamin k antagonists. The anticoagulant drugs market is anticipated to witness the highest growth rate due to its ability to generate less rate of strokes amongst the patients of atrial fibrillation. On the basis of application, the market can be divided into heart rhythm control and heart rate control. The heart rhythm control market is expected to dominate the market and witness the highest growth rate due to high requirements for restoration of sinus rhythm and rise in geriatric population. On the basis of the route of administration, the market can be divided into oral and injectable. Oral atrial fibrillation is expected to dominate the market due to its better effectiveness for prevention of blood clots. On the basis of end-use, the market can be divided into hospitals, cardiac centres, and ambulatory surgical centres. Hospitals are expected to dominate the market due to high availability of drug therapies and a large number of supply agreements of drugs with producers.

The surge in the number of people suffering from cardiovascular diseases is the major driver for market growth. The rapid increase in the geriatric population is another significant factor driving the growth of the market. The evident change in the lifestyles of people involving unhealthy eating habits, rise in junk food consumption, reduction in exercise time, rise in obesity are the primary causes for the increase in health-related diseases like diabetes. Direct cardioversion intervention is not necessary for some patient, and they utilise atrial fibrillation drugs that transform the condition to normal sinus rhythm in the patients.

ACCESS FULL REPORT: https://www.fiormarkets.com/report/atrial-fibrillation-drugs-market-by-atrial-fibrillation-type-418211.html

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on sales@fiormarkets.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.